Phentermine Hydrochloride; Topiramate Patent Expiration
Phentermine Hydrochloride; Topiramate is used for managing weight in individuals with obesity or overweight-related comorbidities. It was first introduced by Vivus Llc
Phentermine Hydrochloride; Topiramate Patents
Given below is the list of patents protecting Phentermine Hydrochloride; Topiramate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qsymia | US8580299 | Escalating dosing regimen for effecting weight loss and treating obesity | Jun 14, 2029 | Vivus Llc |
| Qsymia | US8580298 | Low dose topiramate/phentermine composition and methods of use thereof | May 15, 2029 | Vivus Llc |
| Qsymia | US8895057 | Escalating dosing regimen for effecting weight loss and treating obesity | Jun 09, 2028 | Vivus Llc |
| Qsymia | US8895058 | Low dose topiramate/phentermine composition and methods of use thereof | Jun 09, 2028 | Vivus Llc |
| Qsymia | US9011905 | Low dose topiramate/phentermine composition and methods of use thereof | Jun 09, 2028 | Vivus Llc |
| Qsymia | US9011906 | Escalating dosing regimen for effecting weight loss and treating obesity | Jun 09, 2028 | Vivus Llc |
| Qsymia | US7056890 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US7553818 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US7659256 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US7674776 | Combination therapy for effecting weight loss and treating obesity |
Jun 14, 2020
(Expired) | Vivus Llc |
| Qsymia | US6071537 | Anticonvulsant derivatives useful in treating obesity |
Jun 23, 2017
(Expired) | Vivus Llc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Phentermine Hydrochloride; Topiramate's patents.
Latest Legal Activities on Phentermine Hydrochloride; Topiramate's Patents
Given below is the list recent legal activities going on the following patents of Phentermine Hydrochloride; Topiramate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011905(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011906(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895058(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8895057(Litigated) |
| Expire Patent Critical
| 11 Apr, 2022 | US7674776(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 25 Oct, 2021 | US7674776(Litigated) |
| Expire Patent Critical
| 02 Aug, 2021 | US7553818(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580299(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Apr, 2021 | US8580298(Litigated) |
| Maintenance Fee Reminder Mailed Critical
| 15 Feb, 2021 | US7553818(Litigated) |
Phentermine Hydrochloride; Topiramate's Family Patents
